TY - JOUR
T1 - Electroceuticals in the Gastrointestinal Tract
AU - Ramadi, Khalil B.
AU - Srinivasan, Shriya S.
AU - Traverso, Giovanni
N1 - Funding Information:
K.B.R. was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH under award F32DK122762 . S.S. was supported by the Schmidt Science Fellows program. G.T. was supported in part by the Karl van Tassel (1925) Career Development Professorship, Department of Mechanical Engineering, Massachusetts Institute of Technology, a grant from Novo Nordisk , NIH grant EB000244 , and grant INV-002177 from the Bill and Melinda Gates Foundation .
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/12
Y1 - 2020/12
N2 - The field of electroceuticals has attracted considerable attention over the past few decades as a novel therapeutic modality. The gastrointestinal (GI) tract (GIT) holds significant potential as a target for electroceuticals as the intersection of neural, endocrine, and immune systems. We review recent developments in electrical stimulation of various portions of the GIT (including esophagus, stomach, and small and large intestine) and nerves projecting to the GIT and supportive organs. This has been tested with varying degrees of success for several dysmotility, inflammatory, hormonal, and neurologic disorders. We outline a vision for the future of GI electroceuticals, building on advances in mechanistic understanding of GI physiology coupled with novel ingestible technologies. The next wave of electroceutical therapies will be minimally invasive and more targeted than current approaches, making them an indispensable tool in the clinical armamentarium.
AB - The field of electroceuticals has attracted considerable attention over the past few decades as a novel therapeutic modality. The gastrointestinal (GI) tract (GIT) holds significant potential as a target for electroceuticals as the intersection of neural, endocrine, and immune systems. We review recent developments in electrical stimulation of various portions of the GIT (including esophagus, stomach, and small and large intestine) and nerves projecting to the GIT and supportive organs. This has been tested with varying degrees of success for several dysmotility, inflammatory, hormonal, and neurologic disorders. We outline a vision for the future of GI electroceuticals, building on advances in mechanistic understanding of GI physiology coupled with novel ingestible technologies. The next wave of electroceutical therapies will be minimally invasive and more targeted than current approaches, making them an indispensable tool in the clinical armamentarium.
KW - electrical stimulation
KW - electroceuticals
KW - gastrointestinal tract
UR - http://www.scopus.com/inward/record.url?scp=85094608835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094608835&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2020.09.014
DO - 10.1016/j.tips.2020.09.014
M3 - Review article
C2 - 33127099
AN - SCOPUS:85094608835
SN - 0165-6147
VL - 41
SP - 960
EP - 976
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
IS - 12
ER -